title: Percutaneous transluminal intervention and antiplatelet therapy following endovascular graft exclusion for Stanford B thoracic aortic dissection.
abstract: OBJECTIVE
  To evaluate the safety and feasibility of percutaneous coronary intervention and antiplatelet therapy in patients who have undergone endovascular graft exclusion.
  
  
  METHODS
  From January 2005 to July 2007, percutaneous transluminal intervention (PCI) was performed in 13 patients who had undergone endovascular graft exclusion for the treatment of either acute or chronic Stanford B aortic dissection. Anticoagulant and antiplatelet treatments were administered according to the standard protocol. Patients were followed up for a mean period of 11 months. Clinical characteristics, false lumen thrombosis and angiographic data were collected.
  
  
  RESULTS
  PCI was technically successful in all 13 patients and no severe complications, including death, paraplegia or renal failure occurred during hospitalization. Complete false lumen thrombosis was observed in all patients within 6 months. There were no major complications such as death, dissection rupture, or aneurysm development during the follow-up period.
  
  
  CONCLUSIONS
  Our data suggested that PCI and standard antiplatelet therapy are feasible and safe in patients who have undergone endovascular stent graft exclusion for Stanford B aortic dissection.
authors.affiliation: Department of Cardiology, Shenyang Northern Hospital, Shenyang 110016, China.
authors.forename: Quanmin
authors.initials: Q
authors.lastname: Jing
authors.forename: Liang
authors.initials: L
authors.lastname: Guo
authors.forename: Xiaozeng
authors.initials: X
authors.lastname: Wang
authors.forename: Bo
authors.initials: B
authors.lastname: Luan
authors.forename: Geng
authors.initials: G
authors.lastname: Wang
authors.forename: Xiaojiang
authors.initials: X
authors.lastname: Liu
authors.forename: Hongxu
authors.initials: H
authors.lastname: Jin
authors.forename: Yaling
authors.initials: Y
authors.lastname: Han
mesh_terms: D000328:Adult; D000368:Aged; D000784:Aortic Dissection / Q000175:diagnosis / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D017545:Aortic Aneurysm, Thoracic / Q000175:diagnosis / Q000628:therapy*; D001807:Blood Vessel Prosthesis / Q000009:adverse effects; D015331:Cohort Studies; D057510:Endovascular Procedures / Q000009:adverse effects / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors